Physicians typically do not overestimate the overall health of people with ANCA-associated vasculitis (AAV), a study of global assessments…
Articles by Margarida Maia, PhD
Adicet Bio has pushed to the second half of 2025 the expected timing for enrolling patients with ANCA-associated…
More than half of the people living with ANCA-associated vasculitis (AAV) have infections caused by bacteria, fungi, or viruses,…
Q32 Bio is delaying the start of a planned Phase 2 clinical trial designed to test its ADX-097 therapy…
Being frail, that is, more vulnerable to health stressors as a result of aging-related biological changes, may put older adults…
People with ANCA-associated vasculitis (AAV) who carry certain variants in SERPINA1 — a gene that’s been previously linked to…
Low blood levels of glial fibrillary acidic protein (GFAP) are linked to more active disease and a higher risk of…
Combination maintenance therapy with Nucala (mepolizumab) and azathioprine may be more effective than either treatment alone at maintaining disease…
Tavneos (avacopan) effectively induces disease remission in adults with ANCA-associated vasculitis (AAV) and diffuse alveolar hemorrhage (DAH), that…
Nearly one year of treatment with rituximab was superior to traditional immunosuppressive medications at helping people with ANCA-associated…